Millendo Therapeutics, Inc. (MLND) relating to its proposed merger with Tempest Therapeutics, Inc. Under the terms of the agreement, MLND shareholders are expected to own 18.5% of the combined company.
Millendo Therapeutics, Inc. (MLND) relating to its proposed merger with Tempest Therapeutics, Inc. Under the terms of the agreement, MLND shareholders are expected to own 18.5% of the combined company.